By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


SEARCH JOBS

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).


Key Statistics


Email:
Ownership: Public

Web Site: Ariad
Employees:
Symbol: ARIA
 









Company News
Ariad (ARIA) To Webcast Conference Call On Fourth Quarter And Year-End 2015 Financial Results 2/2/2016 11:37:09 AM
Ariad (ARIA) Announces FDA Clearance To Begin Clinical Development Of AP32788 2/1/2016 11:01:40 AM
New Chairman at Struggling Ariad (ARIA) Reassure Investors that a Sale Will Only be Made if the Deal is Right 1/19/2016 6:42:06 AM
Ariad (ARIA) Reports Inducement Grant To New Chief Executive Officer 1/15/2016 9:18:00 AM
Ariad (ARIA) Announces Termination Of Shareholder Rights Plan 1/11/2016 2:14:16 PM
Ariad (ARIA) Announces Election Of Alex Denner As Chairman Of The Board Of Directors 1/11/2016 12:36:04 PM
Ariad (ARIA) And Otsuka Pharma Submit New Drug Application In Japan For Ponatinib 1/8/2016 12:01:17 PM
Struggling Ariad (ARIA) Nets Former Merck KGaA (MKGAF.PK) Exec as New CEO 12/18/2015 6:17:45 AM
Ariad (ARIA) Announces Pricing And Reimbursement Negotiations For Iclusig In France To Continue Into 2016 12/11/2015 10:57:44 AM
Ariad (ARIA) Announces Initiation Of OPTIC-2L Randomized Phase 3 Trial Of Ponatinib Vs. Nilotinib In Second-Line Patients With Chronic-Phase Chronic Myeloid Leukemia 12/7/2015 1:04:37 PM
12345678910...
//-->